Decreased potency of MDR‐modulators under serum conditions determined by a functional assay

Multiple-Drug Resistance in Human Cancer

1987 • 703 citations

Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.

1989 • 565 citations

A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and In vitro anti‐proliferative as well as In vivo anti‐tumor activity

1989 • 414 citations

P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil.

1991 • 388 citations

In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833.

1991 • 364 citations

Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes [see comments]

1992 • 347 citations

Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen.

1994 • 334 citations

Modulation of multidrug-resistant multiple myeloma by cyclosporin

1992 • 317 citations

Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.

1992 • 298 citations

Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes [see comments]

1992 • 290 citations

Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia.

1993 • 284 citations

Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer

1991 • 228 citations

Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.

1994 • 186 citations

Detection of activity of P‐glycoprotein in human tumour samples using rhodamine 123

1992 • 172 citations

Multidrug resistance in lymphomas.

1994 • 115 citations

Multidrug Resistance: Molecular Biology Clinical Relevance

1989 • 114 citations

Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial.

1994 • 101 citations

Molecular Targets in Oncology: Implications of the Multidrug Resistance Gene

1993 • 94 citations

Clinical relevance of P-glycoprotein expression in haematological malignancies

1994 • 93 citations

The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance

1994 • 73 citations

Activity of P-Glycoprotein in B-Cell Chronic Lymphocytic Leukemia Determined by a Flow Cytometric Assay

1993 • 52 citations

Reversal of multidrug resistance by B859-35, a metabolite of B859-35, niguldipine, verapamil and nitrendipine

1992 • 51 citations

Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo

1992 • 29 citations

Clinical reversal of the multidrug resistance phenotype: True tumour modulation or pharmacokinetic interaction?

1994 • 27 citations

SDZ PSC 833 in combination with doxorubicin

1994 • 9 citations

Southwest Oncology Group clinical trials of chemosensitizers in non-Hodgkinʼs lymphomas

1994 • 6 citations

R-verapamil reverses drug resistance in some relapsed lymphoma patients

1994 • 3 citations

Deleted Work

1955 • 0 citations